PMEF
EIGR

Point72 Middle East FZE’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Point72 Middle East FZE’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-105
Closed -$2.22K – 1992
2023
Q2 		$2.22K Buy
+105
New +$3.23K ﹤0.01% 1461

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Middle East FZE's EIGR Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 105 shares — an estimated $2.22K sold.

Point72 Middle East FZE first reported a position in EIGR in Q2 2023 and held it in 1 quarter. The position peaked at $2.22K in Q2 2023. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 105 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $2.22K.
  • Point72 Middle East FZE first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Eiger BioPharmaceuticals, Inc. position peaked at $2.22K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.